Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.
paper
Cited
Public
Unavailable
- Authors
- Topol, Eric J; Bousser, Marie-Germaine; Fox, Keith A A; Creager, Mark A; Despres, Jean-Pierre; Easton, J Donald; Hamm, Christian W; Montalescot, Gilles; Steg, P Gabriel; Pearson, Thomas A; Cohen, Eric; Gaudin, Christophe; Job, Bernard; Murphy, Judith H; Bhatt, Deepak L; CRESCENDO Investigators
- Year
- 2010
- Journal
- Lancet (London, England)
- PMID
- 20709233
- DOI
- 10.1016/S0140-6736(10)60935-X
BACKGROUND: Blockade of the endocannabinoid receptor reduces obesity and improves metabolic abnormalities such as triglycerides, HDL cholesterol, and fasting blood glucose. We assessed whether rimonabant would improve major vascular event-free survival. METHODS: This double-blind, placebo-controlled trial was undertaken in 974 hospitals in 42 countries. 18,695 patients with previously manifest or increased risk of vascular disease were randomly assigned to receive either rimonabant 20 mg (n=9381) or matching placebo (n=9314). Randomisation was stratified by centre, implemented with an independent interactive voice response system, and all study personnel and participants were masked to group assignment. The primary endpoint was the composite of cardiovascular death, myocardial infarction, or stroke, as determined via central adjudication. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00263042. FINDINGS: At a mean follow-up of 13.8 months (95% CI 13.6-14.0), the trial was prematurely discontinued because of concerns by health regulatory authorities in three countries about suicide in individuals receiving rimonabant. All randomised participants were analysed. At the close of the trial (Nov 6, 2008), the composite primary endpoint of cardiovascular death, myocardial infarction, or stroke occurred in 364 (3.9%) patients assigned to rimonabant and 375 (4.0%) assigned to placebo (hazard ratio 0.97, 95% CI 0.84-1.12, p=0.68). With rimonabant, gastrointestinal (3038 [33%] vs 2084 [22%]), neuropsychiatric (3028 [32%] vs 1989 [21%]), and serious psychiatric side-effects (232 [2.5%] vs 120 [1.3%]) were significantly increased compared with placebo. Four patients in the rimonabant group and one in the placebo group committed suicide. INTERPRETATION: The premature termination of this trial has important lessons for drug development. A drug that was being marketed for weight loss, but being tested for improving cardiovascular outcomes, induced a level of serious neuropsychiatric effects that was deemed unacceptable by regulatory authorities, and both the drug and the trial were abruptly terminated. FUNDING: Sanofi-Aventis.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines. | Platz E et al. | β | 2026 | β |
| Discrete Choice Experiment (DCE) as a Tool to Elicit Patient Preferences in a Complex Benefit-Risk Evaluation: A Case Study. | E JY et al. | β | 2026 | β |
| Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery. | Tian L et al. | β | 2025 | β |
| Exploration of (R)-[<sup>11</sup>C]YH168 as a PET tracer for imaging monoacylglycerol lipase in the brain: from mice to non-human primates. | He Y et al. | β | 2025 | β |
| Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy. | Vigano M et al. | β | 2025 | β |
| Incretin-based therapy: An update focusing on the major revolution in cardiovascular-kidney-metabolic health. | Chiang CE et al. | β | 2025 | β |
| Mood Disorders, Metabolic Bariatric Surgery, and Weight Loss Pharmacotherapy: a Research Update. | Barbuti M et al. | β | 2025 | β |
| Obesity and Cardiometabolic Disease: Insights From Genetic Studies. | Dash S | β | 2025 | β |
| Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. | Kushner RF et al. | β | 2025 | β |
| The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment. | Packer M | β | 2025 | β |
| The Role of Fatty Acid Binding Proteins in Neuropsychiatric Diseases: A Narrative Review. | Powell A et al. | β | 2025 | β |
| Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. | Lam CSP et al. | β | 2025 | β |
| Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. | Sidrak WR et al. | β | 2024 | β |
| Brain region specific regulation of anandamide (down) and sphingosine-1-phosphate (up) in association with anxiety (AEA) and resilience (S1P) in a mouse model of chronic unpredictable mild stress. | Fischer C et al. | β | 2024 | β |
| Brain region specific regulation of anandamide (down) and sphingosine-1- phosphate (up) in association with anxiety (AEA) and resilience (S1P) in a mouse model of chronic unpredictable mild stress | Fischer C et al. | β | 2024 | β |
| Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies. | Duncan RS et al. | β | 2024 | β |
| Dissecting the role of cannabinoids in vascular health and disease. | Guo Y et al. | β | 2024 | β |
| Peripheral endocannabinoids in major depressive disorder and alcohol use disorder: a systematic review. | Fuentes JJ et al. | β | 2024 | β |
| Resistin Regulates Inflammation and Insulin Resistance in Humans via the Endocannabinoid System. | Yang HM et al. | β | 2024 | β |
| Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile. | Cohen Y et al. | β | 2024 | β |
| Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review. | Alsaqaaby MS et al. | β | 2024 | β |
| Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal? | Lau D et al. | β | 2024 | β |
| The need for guidance in antidepressant drug development: Revisiting the role of the forced swim test and tail suspension test. | Trunnell ER et al. | β | 2024 | β |
| Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. | Mock ED et al. | β | 2023 | β |
| A review of the evidence on cardiovascular outcomes from obesity treatment. | Abdul Wahab R et al. | β | 2023 | β |
| Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders. | Royse SK et al. | β | 2023 | β |
| Cannabinoid Signaling in Kidney Disease. | Arceri L et al. | β | 2023 | β |
| Does tobacco dependence worsen cannabis withdrawal in people with and without schizophrenia-spectrum disorders? | Yeap ZJS et al. | β | 2023 | β |
| Editorial commentary: Weight loss for cardiovascular disease prevention - is semaglutide the answer? | Lavie CJ et al. | β | 2023 | β |
| Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity. | Vasincu A et al. | β | 2023 | β |
| Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? | Kloock S et al. | β | 2023 | β |
| Recent advances in the treatment of patients with obesity and chronic kidney disease. | Abdul Wahab R et al. | β | 2023 | β |
| Role of Cannabinoid Signaling in Cardiovascular Function and Ischemic Injury. | Rorabaugh BR et al. | β | 2023 | β |
| Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity. | Michos ED et al. | β | 2023 | β |
| Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. | Lingvay I et al. | β | 2023 | β |
| Association between cannabis use and suicidal behavior: A systematic review of cohort studies. | Carvalho JV et al. | β | 2022 | β |
| A Literature Review of Cannabis and Myocardial Infarction-What Clinicians May Not Be Aware Of. | Chetty K et al. | β | 2021 | β |
| Antipsychotics cardiotoxicity: What's known and what's next. | Li XQ et al. | β | 2021 | β |
| Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox. | Dao M et al. | β | 2021 | β |
| Cannabinoid Receptors in Myocardial Injury: A Brother Born to Rival. | Tang X et al. | β | 2021 | β |
| Cardiovascular outcome trials in obesity: A review. | Wilding JPH et al. | β | 2021 | β |
| CB1 Cannabinoid Receptor Signaling and Biased Signaling. | Leo LM et al. | β | 2021 | β |
| Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers. | Morel A et al. | β | 2021 | β |
| Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. | Ng ACT et al. | β | 2021 | β |
| Intermittent fasting for the prevention of cardiovascular disease. | Allaf M et al. | β | 2021 | β |
| Long-term effects of weight-reducing drugs in people with hypertension. | Siebenhofer A et al. | β | 2021 | β |
| The Endocannabinoid System and Cannabidiol: Past, Present, and Prospective for Cardiovascular Diseases. | Rabino M et al. | β | 2021 | β |
| Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases. | Haspula D et al. | β | 2020 | β |
| Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat. | Castonguay-Paradis S et al. | β | 2020 | β |
| Differential effect of interferon-alpha treatment on AEA and 2-AG levels. | Zajkowska Z et al. | β | 2020 | β |
| Marijuana Use in Patients With CardiovascularΒ Disease: JACC Review Topic of the Week. | DeFilippis EM et al. | β | 2020 | β |
| Repurposing existing drugs for COVID-19: an endocrinology perspective. | Cadegiani FA | β | 2020 | β |
| Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs. | Murphy T et al. | β | 2020 | β |
| The therapeutic potential of second and third generation CB<sub>1</sub>R antagonists. | Cinar R et al. | β | 2020 | β |
| Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension : A Randomized Clinical Trial. | Schiavon CA et al. | β | 2020 | β |
| Cannabinoid Signaling in the Skin: Therapeutic Potential of the "C(ut)annabinoid" System. | TΓ³th KF et al. | β | 2019 | β |
| Cannabis effects on lipoproteins. | Lazarte J et al. | β | 2019 | β |
| Cardiometabolic risk reduction after metabolic surgery. | Pareek M et al. | β | 2019 | β |
| Countering the Modern Metabolic Disease Rampage With Ancestral Endocannabinoid System Alignment. | Pepper I et al. | β | 2019 | β |
| Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies. | Sloan ME et al. | β | 2019 | β |
| GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice. | DΓ©carie-Spain L et al. | β | 2019 | β |
| Lorcaserin for prevention and remission of type 2 diabetes mellitus in people with overweight or obesity: protocol for a systematic review and meta-analysis. | Zeng H et al. | β | 2019 | β |
| Opportunities for cannabis in supportive care in cancer. | Kleckner AS et al. | β | 2019 | β |
| Opposite effects of cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptors on antipsychotic clozapine-induced cardiotoxicity. | Li L et al. | β | 2019 | β |
| Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. | Pacher P et al. | β | 2018 | β |
| Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. | Bohula EA et al. | β | 2018 | β |
| Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. | Bohula EA et al. | β | 2018 | β |
| Is cannabis a risk factor for suicide attempts in men and women with psychotic illness? | Waterreus A et al. | β | 2018 | β |
| Kinetics of human cannabinoid 1 (CB1) receptor antagonists: Structure-kinetics relationships (SKR) and implications for insurmountable antagonism. | Xia L et al. | β | 2018 | β |
| New approaches and challenges to targeting the endocannabinoid system. | Di Marzo V | β | 2018 | β |
| Selective up-regulation of cannabinoid CB<sub>1</sub> receptor coupling to Go-proteins in suicide victims with mood disorders. | Mato S et al. | β | 2018 | β |
| Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment. | Bozinoff N et al. | β | 2018 | β |
| Animal models to improve our understanding and treatment of suicidal behavior. | Gould TD et al. | β | 2017 | β |
| Antidote to cannabinoid intoxication: the CB<sub>1</sub> receptor inverse agonist, AM251, reverses hypothermic effects of the CB<sub>1</sub> receptor agonist, CB-13, in mice. | Pryce G et al. | β | 2017 | β |
| Cannabinoids in the Cardiovascular System. | Ho WSV et al. | β | 2017 | β |
| Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT<sub>1A</sub> receptor. | McLaughlin PJ et al. | β | 2017 | β |
| Food for Thought: Reward Mechanisms and Hedonic Overeating in Obesity. | Lee PC et al. | β | 2017 | β |
| Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: a retrospective cohort study. | Agrawal A et al. | β | 2017 | β |
| MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future. | Simon V et al. | β | 2017 | β |
| Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. | Kimberly WT et al. | β | 2017 | β |
| Past, present and future of pharmacotherapy for obesity. | Benaiges D et al. | β | 2017 | β |
| Structure-Affinity Relationships and Structure-Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists. | Xia L et al. | β | 2017 | β |
| Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges. | OlΓ‘h A et al. | β | 2017 | β |
| The endocannabinoid system as a target for addiction treatment: Trials and tribulations. | Sloan ME et al. | β | 2017 | β |
| Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. | Peres FF et al. | β | 2016 | β |
| Cannabinoid Receptor 2 as Antiobesity Target: Inflammation, Fat Storage, and Browning Modulation. | Rossi F et al. | β | 2016 | β |
| Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression? | Boorman E et al. | β | 2016 | β |
| Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases. | Cameron RB et al. | β | 2016 | β |
| Exercise versus targeting of endocannabinoid system for atheromatic plaque stabilization. Opposing or complementary roles? | Toutouzas K et al. | β | 2016 | β |
| Interaction between interleukin-1Ξ² and type-1 cannabinoid receptor is involved in anxiety-like behavior in experimental autoimmune encephalomyelitis. | Gentile A et al. | β | 2016 | β |
| Long-term effects of weight-reducing drugs in people with hypertension. | Siebenhofer A et al. | β | 2016 | β |
| Neurobiological Interactions Between Stress and the Endocannabinoid System. | Morena M et al. | β | 2016 | β |
| Novel Treatments for Cyclic Vomiting Syndrome: Beyond Ondansetron and Amitriptyline. | Bhandari S et al. | β | 2016 | β |
| Perspectives on Treatment for Nonalcoholic Steatohepatitis. | Lassailly G et al. | β | 2016 | β |
| Role of hypothalamic cannabinoid receptors in post-stroke depression in rats. | Wang S et al. | β | 2016 | β |
| Sevoflurane prevents stroke-induced depressive and anxiety behaviors by promoting cannabinoid receptor subtype I-dependent interaction between Ξ²-arrestin 2 and extracellular signal-regulated kinases 1/2 in the rat hippocampus. | Zhang H et al. | β | 2016 | β |
| Stimulants for the Control of Hedonic Appetite. | Poulton AS et al. | β | 2016 | β |
| Targeting adipose tissue in the treatment of obesity-associated diabetes. | Kusminski CM et al. | β | 2016 | β |
| The role of exercise training and the endocannabinoid system in atherosclerotic plaque burden and composition in Apo-E-deficient mice. | Katsimpoulas M et al. | β | 2016 | β |
| The Role of the Endocannabinoid System in the Brain-Gut Axis. | Sharkey KA et al. | β | 2016 | β |
| Ventral Tegmental Area Afferents and Drug-Dependent Behaviors. | Oliva I et al. | β | 2016 | β |
| 4-Year Cost Trajectories in Real-World Patients Matched to the Metabolic Profiles of Trial Subjects Before/After Treatment with Phentermine-Topiramate. | Li J et al. | β | 2015 | β |
| A cannabinoid receptor 1 polymorphism is protective against major depressive disorder in methadone-maintained outpatients. | Icick R et al. | β | 2015 | β |
| A concise review of non-alcoholic fatty liver disease. | Than NN et al. | β | 2015 | β |
| Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model. | Straiker A et al. | β | 2015 | β |
| Association between paracetamol use in infancy or childhood with body mass index. | Murphy R et al. | β | 2015 | β |
| Cardiovascular pharmacotherapy: Innovation stuck in translation. | Rongen GA et al. | β | 2015 | β |
| Lipid Abundance in Zebrafish Embryos Is Regulated by Complementary Actions of the Endocannabinoid System and Retinoic Acid Pathway. | Fraher D et al. | β | 2015 | β |
| Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. | Carey CE et al. | β | 2015 | β |
| New targets to treat obesity and the metabolic syndrome. | Martin KA et al. | β | 2015 | β |
| The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. | Jones BJ et al. | β | 2015 | β |
| Why are anti-obesity drugs stigmatized? | Halpern B et al. | β | 2015 | β |
| A stepwise likelihood ratio test procedure for rare variant selection in case-control studies. | Kuk AY et al. | β | 2014 | β |
| Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. | Jordan J et al. | β | 2014 | β |
| Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. | Scheen AJ et al. | β | 2014 | β |
| Endocannabinoid signaling in the etiology and treatment of major depressive illness. | Hillard CJ et al. | β | 2014 | β |
| Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. | Kernan WN et al. | β | 2014 | β |
| Have the genetics of cannabis involvement gone to pot? | Agrawal A et al. | β | 2014 | β |
| Incidence of cancer following bariatric surgery: systematic review and meta-analysis. | Casagrande DS et al. | β | 2014 | β |
| Modelling cognitive affective biases in major depressive disorder using rodents. | Hales CA et al. | β | 2014 | β |
| Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. | Cunningham JW et al. | β | 2014 | β |
| Polyunsaturated fatty acids and their metabolites in brain function and disease. | Bazinet RP et al. | β | 2014 | β |
| Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. | Tam J et al. | β | 2014 | β |
| Towards a personalized treatment in depression: endocannabinoids, inflammation and stress response. | Zajkowska ZE et al. | β | 2014 | β |
| Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). | Jones WS et al. | β | 2014 | β |
| 50 years of hurdles and hope in anxiolytic drug discovery. | Griebel G et al. | β | 2013 | β |
| Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. | Boughton CK et al. | β | 2013 | β |
| CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans. | Bergholm R et al. | β | 2013 | β |
| CB1 cannabinoid receptor deficiency promotes cardiac remodeling induced by pressure overload in mice. | Liao Y et al. | β | 2013 | β |
| Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. | Leonardi S et al. | β | 2013 | β |
| Managing cardiovascular risk in overweight children and adolescents. | Dhuper S et al. | β | 2013 | β |
| Manipulating molecular switches in brown adipocytes and their precursors: a therapeutic potential. | Birerdinc A et al. | β | 2013 | β |
| Setting the record straight on TIDE: a lost opportunity for patients with diabetes. | Punthakee Z et al. | β | 2013 | β |
| Significance of Kampo, Japanese traditional medicine, in the treatment of obesity: basic and clinical evidence. | Yamakawa J et al. | β | 2013 | β |
| Strategies for preventing type 2 diabetes: an update for clinicians. | Khavandi K et al. | β | 2013 | β |
| Synthetic strategies for radioligands for in vivo imaging of brain cannabinoid type-1 receptors. | Ahamed M et al. | β | 2013 | β |
| The unrelenting fall of the pharmacological treatment of obesity. | Di Dalmazi G et al. | β | 2013 | β |
| Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. | Hill MN et al. | β | 2013 | β |
| Cannabinoid receptor genotype moderation of the effects of childhood physical abuse on anhedonia and depression. | Agrawal A et al. | β | 2012 | β |
| Cannabinoids and atherosclerotic coronary heart disease. | Singla S et al. | β | 2012 | β |
| Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. | Engeli S | β | 2012 | β |
| Chapter 2: Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients. | β | β | 2012 | β |
| Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice. | Liao Y et al. | β | 2012 | β |
| Drug treatment of obesity in cardiovascular disease. | Charakida M et al. | β | 2012 | β |
| Early intervention of intravenous KB220IV--neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study. | Miller M et al. | β | 2012 | β |
| Food and Drug Administration's Obesity Drug Guidance Document: a short history. | Colman E | β | 2012 | β |
| Interleukin-1Ξ² causes anxiety by interacting with the endocannabinoid system. | Rossi S et al. | β | 2012 | β |
| Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. | Jordan J et al. | β | 2012 | β |
| Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. | He H et al. | β | 2012 | β |
| Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction. | Barton M et al. | β | 2012 | β |
| Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels. | Lynch CJ et al. | β | 2012 | β |
| The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. | HorvΓ‘th B et al. | β | 2012 | β |
| The role of intravascular ultrasound in the determination of progression and regression of coronary artery disease. | Kaneda H et al. | β | 2012 | β |
| Update on the endocannabinoid-mediated regulation of gelatinase release in arterial wall physiology and atherosclerotic pathophysiology. | Michel-Monigadon D et al. | β | 2012 | β |
| Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis. | Waters DD | β | 2012 | β |
| A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. | Barnhart KF et al. | β | 2011 | β |
| Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk. | Janero DR et al. | β | 2011 | β |
| Cannabinoid type 1 receptor antagonists for smoking cessation. | Cahill K et al. | β | 2011 | β |
| Commentary: the need for clinical freedom. | Hampton J | β | 2011 | β |
| Dedicated to evidence-based medicine and the evaluation of new therapeutic approaches in the field. | Schindler C | β | 2011 | β |
| Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. | O'Leary DH et al. | β | 2011 | β |
| Energy balance regulation by endocannabinoids at central and peripheral levels. | Quarta C et al. | β | 2011 | β |
| Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. | Sciolino NR et al. | β | 2011 | β |
| European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. | Jordan J et al. | β | 2011 | β |
| Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find? | Downey M et al. | β | 2011 | β |
| Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. | Bays HE | β | 2011 | β |
| Obesity and inflammatory vasculopathy: a surgical solution as ultima ratio? | Heusch G | β | 2011 | β |
| Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice. | Hu C et al. | β | 2011 | β |
| Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. | Wierzbicki AS et al. | β | 2011 | β |
| The dismal fat, kidney and brain connection: what to do? | Reuter J et al. | β | 2011 | β |
| The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. | Miller LK et al. | β | 2011 | β |
| The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. | AIM-HIGH Investigators | β | 2011 | β |
| [Update in ischemic heart disease]. | BarrabΓ©s JA et al. | β | 2011 | β |
| Prevention: Neuropsychiatric adverse effects signal the end of the line for rimonabant. | King A | β | 2010 | β |
| Rimonabant: obituary for a wonder drug. | Boekholdt SM et al. | β | 2010 | β |
| Termination of the CRESCENDO trial. | Kwatra SG | β | 2010 | β |
| Termination of the CRESCENDO trial. | Roberfroid D et al. | β | 2010 | β |